Hercules Capital, Inc. provides senior secured venture growth loans to high-growth, venture capital-backed and institutional-backed companies, with an emphasis on technology and life sciences industries. Its updates commonly address debt and equity commitments, loan fundings, portfolio-company financings, net investment income, net asset value, leverage, available liquidity and recurring cash distributions.
Hercules also reports developments involving credit ratings, annual meeting and proxy matters, executive leadership, and its asset management activity through Hercules Adviser LLC and related Adviser Funds. The company’s common stock trades on the NYSE under HTGC, and its retail notes trade under HCXY.
Summary not available.
Perk, an AI-native travel and spend management platform, closed a $300 million private credit facility led by Neuberger Specialty Finance with participation from Blue Owl Capital (NYSE: OWL), Hercules Capital and Liquidity.
The facility replaces Perk’s 2024 credit line on improved terms and supports global growth, after 2025 annualized revenue topped $300 million with 48% revenue growth and gross margins rising from 40% to the mid-70s over three years.
Hercules Capital (NYSE: HCXY) will hold its 2026 Annual Meeting of Stockholders virtually on June 18, 2026 at 9:00 a.m. Eastern Time. The proxy statement was filed April 23, 2026 for holders of record as of April 9, 2026.
Matters to be voted on include director election, advisory votes on executive compensation and frequency, amendments to the 2018 Equity Incentive Plan and 2018 Non-Employee Director Plan, and ratification of PricewaterhouseCoopers LLP as independent auditors for 2026.
Hercules Capital (NYSE: HCXY) reported Q1 2026 results with record $1.81B total new debt and equity commitments (+77.8% YoY) and $706.4M total fundings (+31.0% YoY). Q1 investment income was $141.5M and NII was $88.1M ($0.48 per share), providing 120% coverage of the base cash distribution. Closed a $300.0M institutional notes offering at 5.350% due 2029. Assets under management were approximately $6.1B (+21.8% YoY) with over $1.0B available liquidity and reported net GAAP leverage of 113.5%.
Hercules Capital announced executive leadership changes effective May 18, 2026: Seth Meyer, CFO since 2019, is promoted to President, and Andrew Olson is named Chief Financial Officer and Head of Corporate Development. Meyer will focus on scaling the platform; Olson returns with 19+ years in private credit, alternative asset finance, and prior Hercules experience.
Hercules Capital (NYSE: HTGC) declared a $0.47 per share total cash distribution for Q1 2026, comprising a $0.40 base and $0.07 supplemental distribution.
The record date is May 14, 2026 and the payment date is May 21, 2026. Hercules reported that 100% of Q1 distributions were from current and accumulated earnings and profits, and 78.54% of the distribution qualifies as Qualified Interest Income for U.S. withholding purposes for non-U.S. shareholders.
Hercules Capital (NYSE: HTGC) will release its first quarter 2026 financial results after market close on Tuesday, May 5, 2026, and will host a conference call the same day at 2:00 p.m. PT / 5:00 p.m. ET.
Investors can join via telephone or live webcast on the Investor Resources section of the company's website; archived replay will be available online.
Hercules Capital (NYSE: HTGC) reported an all-time record of $1.81 billion in new debt and equity commitments for Q1 2026. The company originated commitments to 16 new and 12 existing portfolio companies, and expanded financings for several existing holdings.
Management said the firm’s scale, balance sheet and liquidity position it to pursue originations during 2026 market volatility.
enGene (Nasdaq: ENGN) reported Q1 2026 results and provided a development update for detalimogene voraplasmid. Key highlights: $312.5 million cash and marketable securities providing runway into 2H 2028, expanded $125 million Hercules debt facility, and $140.1 million net proceeds from a Nov 2025 offering.
LEGEND pivotal cohort showed promising efficacy (63% CR any time; 56% CR at 3 months; 62% CR at 6 months). enGene plans a BLA submission and expects 12-month data and a conference update in 2026.
Hercules Capital (NYSE: HCXY) announced that Morningstar DBRS affirmed its BBB (high) investment grade corporate and credit rating with a Stable trend on March 4, 2026. DBRS cited the company’s franchise strength, resilient earnings, sound asset credit performance, funding depth and disciplined leverage.
DBRS placed Hercules at the top end of its business development company peer-range and noted the company is positioned to weather volatility from moderating growth and AI-related sentiment, while its software originations focus on firms with domain expertise and higher switching costs.